Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

217 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
Hunter SJ, Shaw JA, Lee KO, Wood PJ, Atkinson AB, Bevan JS. Hunter SJ, et al. Among authors: atkinson ab. Clin Endocrinol (Oxf). 1999 Feb;50(2):245-51. doi: 10.1046/j.1365-2265.1999.00668.x. Clin Endocrinol (Oxf). 1999. PMID: 10396369 Clinical Trial.
Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM. Bevan JS, et al. Among authors: atkinson ab. J Clin Endocrinol Metab. 2002 Oct;87(10):4554-63. doi: 10.1210/jc.2001-012012. J Clin Endocrinol Metab. 2002. PMID: 12364434 Clinical Trial.
Bromocriptine reduces growth hormone in acromegaly.
Bell PM, Atkinson AB, Hadden DR, Kennedy L, Leslie H, Merrett JD, Sheridan B. Bell PM, et al. Among authors: atkinson ab. Arch Intern Med. 1986 Jun;146(6):1145-9. Arch Intern Med. 1986. PMID: 3718102
217 results